Supernus Pharmaceuticals, Inc.
NASDAQ:SUPNDrug Manufacturers - Specialty & Generic
+$0.51 today
- Market cap
- $6.02B
- Beta
- 0.54
- P/E (TTM)
- -87.6
- EPS (TTM)
- -$0.50
Volume 2.71M
Average 0.64M
SUPN Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Supernus Pharmaceuticals, Inc.NASDAQ: SUPN
Total Assets · Q2 FY2026 · quarter ended Jun 2026
Total assets rises 3.3% from a year ago
Total assets stood at $1.43B at the end of Q2 FY2026, up 3.3% from a year earlier and down 4.8% from the prior quarter. Over 3 fiscal years it compounded at -5.2% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +3.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.45B USD
- Year-over-year change
- +6.2%
- 4-year CAGR
- -3.7%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.45B | +6.2% |
| FY2024 | 2024-12-31 | 1.37B | +7.1% |
| FY2023 | 2023-12-31 | 1.28B | -25.0% |
| FY2022 | 2022-12-31 | 1.7B | +0.8% |
| FY2021 | 2021-12-31 | 1.69B | — |
Total Assets vs competitors
How SUPN compares with its peers on the latest reported figures
- SUPN's Jun 2026 total assets of $1.43B is the lowest of the 3 companies compared; the peer median is $3.04B.
- Its year-over-year change of +3.3% is the 2nd highest of 3, against a peer median of +45.8%.
- Over three fiscal years its annual growth of -5.2% compares with a peer median of +10.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Sep 2026 | $4.44B | +90.4% | +8.8% | |
| Mar 2026 | $1.65B | +1.3% | +12.2% | |
| Jun 2026 | $1.43B | +3.3% | -5.2% | |
| Peer median (excluding SUPN) | $3.04B | +45.8% | +10.5% | |
Competitors are the stored peer set for SUPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 203.43M | 93.12M | 75.05M | 69.33M | 128.45M |
| Short-term Investments | 136.25M | 368.21M | 179.82M | 384.28M | 180.22M |
| Net Receivables | 148.93M | 165.5M | 144.16M | 142.08M | 187.8M |
| Inventory | 85.96M | 91.54M | 77.41M | 54.29M | 82.39M |
| Other Current Assets | 0 | 15.78M | 16.68M | 36.09M | 65.33M |
| Total Current Assets | 601.59M | 734.15M | 493.11M | 686.07M | 644.18M |
| Property, Plant & Equipment (Net) | 16.96M | 15.17M | 13.53M | 11.55M | 10.53M |
| Goodwill | 117.52M | 117.02M | 117.02M | 117.02M | 124.88M |
| Intangible Assets | 784.69M | 702.46M | 599.89M | 521.91M | 569.46M |
| Long-term Investments | 119.17M | 93.9M | 16.62M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 38.35M |
| Other Non-current Assets | 49.23M | 39.81M | 37.51M | 31.53M | 65.25M |
| Total Non-current Assets | 1.09B | 968.36M | 784.56M | 682M | 808.47M |
| Total Assets | 1.69B | 1.7B | 1.28B | 1.37B | 1.45B |
| Account Payables | 9.33M | 10.54M | 1.96M | 4.59M | 2.68M |
| Short-term Debt | 0 | 401.97M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 93.04M | 54.95M | 77.08M | 68.57M | 98.72M |
| Total Current Liabilities | 315.38M | 687.96M | 290.2M | 292.4M | 338.17M |
| Long-term Debt | 379.25M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 85.36M | 49.81M | 24.96M | 4.96M | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 52.02M | 42.54M | 7.8M | 7.6M | 22.4M |
| Total Non-current Liabilities | 557.92M | 128.35M | 65.96M | 39.94M | 52.76M |
| Total Liabilities | 873.3M | 816.3M | 356.16M | 332.34M | 390.93M |
| Common Stock | 53K | 54K | 55K | 56K | 57K |
| Retained Earnings | 379.92M | 481.25M | 482.56M | 556.43M | 517.88M |
| Accumulated OCI | 1.54M | (3.21M) | (593K) | (189K) | (44K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 815.85M | 886.2M | 921.52M | 1.04B | 1.06B |
| Total Debt | 427.03M | 444.76M | 41.53M | 34.27M | 40.98M |
| Net Debt | 223.59M | 351.64M | (33.53M) | (35.06M) | (87.47M) |
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
Intrinsic Alpha fair value
Locked
Current Price
$28.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.